CDMOs offering Oligonucleotide Manufacturing with mRNA
8 published
8 published CDMOs match Oligonucleotide Manufacturing and mRNA.
Locations in this set include United States, China, India, Singapore, Spain, and Switzerland.
Capabilities that show up most often in this set: CMC Analytical Development, Process Development, mRNA Manufacturing, Quality Control Testing, and Technology Transfer.
Matching companies
BiospringGlobal CDMO leader in nucleic acid manufacturing and analysis (mRNA, ASO, siRNA, guide RNA, oligonucleotides) with nearly three decades of expertise, GMP certification since 2007, and support for 9 commercial programs across all clinical phases.
CordenPharmaFull-service CDMO offering cGMP development and manufacturing of APIs, lipid excipients, drug products, injectables, peptides, LNPs, oligonucleotides, and oral solid dose across 10 facilities in 6 countries with 3000+ employees.
Hongene Biotech CorporationHongene is a vertically-integrated CDMO offering end-to-end oligonucleotide and mRNA manufacturing from raw materials to GMP drug product, with nearly 30 years of RNA-focused expertise and tonne-scale production capacity.
Maravai LifeSciencesLeading provider of nucleic acid products, custom enzymes, and bioprocess analytics supporting vaccine, therapeutic, and diagnostic development from discovery through commercialization, with mRNA CDMO services including proprietary CleanCap® capping technology.
PharmaronPremier life science CRO and CDMO offering integrated R&D and manufacturing across drug discovery, preclinical, clinical development, and commercialization for small molecules, biologics, and cell & gene therapies. 25,000+ employees across China, US, and UK.
Sophia CDMOEuropean CDMO specializing in microbial and precision fermentation up to 40,000 L across two integrated sites (Pamplona, Spain and Basel, Switzerland), with core strengths in E. coli expression, animal health biologics, probiotics, and complex CMC programs requiring scale-up discipline and impurity control.
Syngene InternationalInnovation-led CRDMO offering integrated scientific services from early discovery through commercial manufacturing, with cGMP-compliant facilities, 5,200+ scientists, and a new 50,000-liter single-use bioreactor capacity in the U.S.
TriLink BioTechnologiesTriLink manufactures mRNA, oligonucleotides, and modified nucleotides with proprietary CleanCap® capping technology achieving >95% Cap1 efficiency, supported by in-house analytical method development and a 118,000 sq ft GMP-capable facility.
Markdown mirror: /explore/oligonucleotide-manufacturing/mrna.md